540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Abstract

Entrectinib is a potent, CNS-active ROS1/TRK/ALK inhibitor, which induces clinically meaningful responses in pts with ROS1 fusion-positive (ROS1+) NSCLC and NTRK fusion-positive (NTRK+) solid tumours. We conducted an exploratory analysis to determine if number of prior lines of systemic therapy had any impact on response to entrectinib.